Audentes Therapeutics

OverviewSuggest Edit

Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for patients with serious, rare diseases through the application of gene therapy technology. The Company currently has four programs in development: AT132 for the treatment of X-Linked Myotubular Myopathy, an ultra-rare, severe, debilitating disease that affects skeletal muscles. AT342 for the treatment of Crigler-Najjar Syndrome, a rare, congenital autosomal recessive monogenic disease characterized by severely high levels of bilirubin in the blood and risk of irreversible neurological damage and death. AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia, an inherited disease characterized by abnormal ventricular heartbeats. AT982 for the treatment of Pompe disease, a rare, inherited disorder characterized by progressive muscle weakness and respiratory impairment.
TypePublic
Founded2013
HQSan Francisco, CA, US
Websiteaudentestx.com
Employee Ratings3.4
Overall CultureF

Latest Updates

Employees (est.) (Dec 2018)207(+37%)
Job Openings68
Share Price (Jan 2020)$60
Cybersecurity ratingAMore

Key People/Management at Audentes Therapeutics

Mathew Pletcher

Mathew Pletcher

Division Head of Gene Therapy Research & Technical Operations
Nathan Bachtell

Nathan Bachtell

Senior VP and Head of Gene Therapy, Medical & Development
Megan Baierlein

Megan Baierlein

Senior Vice President and Chief Operating Officer
Chris Lorenz

Chris Lorenz

SVP, Technical Operations
Richard Wilson

Richard Wilson

VP, Program Management & Portfolio Strategy
Fulvio Mavilio

Fulvio Mavilio

Senior Vice President, Translational Science
Show more

Audentes Therapeutics Office Locations

Audentes Therapeutics has an office in San Francisco
San Francisco, CA, US (HQ)
600 California St 17th Floor, San Francisco
Show all (1)

Audentes Therapeutics Financials and Metrics

Audentes Therapeutics Revenue

USD

Net income (Q3, 2019)

(45.7m)

EBIT (Q3, 2019)

(47.8m)

Market capitalization (15-Jan-2020)

2.8b

Closing stock price (15-Jan-2020)

60.0

Cash (30-Sept-2019)

63.6m

EV

2.7b
Audentes Therapeutics's current market capitalization is $2.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

11.3m17.3m30.0m

R&D expense

48.8m75.9m104.4m

Operating expense total

60.0m93.2m134.4m

EBIT

(60.0m)(93.2m)(134.4m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

2.5m2.9m3.7m4.1m4.3m6.5m6.3m7.8m12.0m9.8m10.2m

R&D expense

11.7m12.5m14.6m18.8m20.9m19.9m26.3m29.9m39.8m37.3m37.6m

Operating expense total

14.2m15.5m18.2m22.8m25.2m26.4m32.6m37.7m51.8m47.1m47.8m

EBIT

(14.2m)(15.5m)(18.2m)(22.8m)(25.2m)(26.4m)(32.6m)(37.7m)(51.8m)(47.1m)(47.8m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

36.4m39.0m144.3m

Prepaid Expenses

2.8m3.3m5.5m

Current Assets

108.4m137.0m419.8m

PP&E

18.9m24.4m32.1m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(59.7m)(90.2m)(128.8m)

Depreciation and Amortization

1.6m3.4m5.6m

Accounts Payable

(671.0k)686.0k4.1m

Cash From Operating Activities

(49.0m)(84.5m)(108.0m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(24.6m)(40.0m)(18.1m)(40.9m)(65.9m)(25.6m)(56.9m)(93.2m)(49.4m)(94.2m)(139.9m)

Depreciation and Amortization

289.0k932.0k732.0k1.5m2.4m1.1m2.4m3.9m5.7m

Accounts Payable

(1.2m)(1.1m)(1.2m)640.0k1.2m596.0k(209.0k)(724.0k)1.9m(1.2m)70.0k

Cash From Operating Activities

(26.5m)(36.5m)(22.6m)(38.6m)(61.6m)(24.6m)(47.9m)(79.5m)(42.2m)(83.0m)(118.9m)
USDQ2, 2016

Financial Leverage

1.3 x
Show all financial metrics

Audentes Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Audentes Therapeutics Online and Social Media Presence

Embed Graph

Audentes Therapeutics Company Culture

  • Overall Culture

    F

    42/100

  • CEO Rating

    F

    45/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Audentes Therapeutics Blogs

Astellas Completes Acquisition of Audentes Therapeutics

Astellas Completes Acquisition of Audentes Therapeutics ronfrancis.gon… Wed, 01/15/2020 - 08:41 Astellas Completes Acquisition of Audentes Therapeutics 01/15/20 This release is a backfill from a News Wire General Combined company pos…

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company - Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufacturing

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Content Import Thu, 11/07/2019 - 16:01 Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update 11/07/19 This release is a …

Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019

Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019 Content Import Thu, 10/31/2019 - 07:00 Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7…

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society Content Import Sat, 10/05/2019 - 07:01 Audentes Therapeutics Presen…

Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)

Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM) Content Import Mon, 09/30/2019 - 08:00 Audentes Announc…
Show more

Audentes Therapeutics Frequently Asked Questions

  • When was Audentes Therapeutics founded?

    Audentes Therapeutics was founded in 2013.

  • Who are Audentes Therapeutics key executives?

    Audentes Therapeutics's key executives are Mathew Pletcher, Nathan Bachtell and Megan Baierlein.

  • How many employees does Audentes Therapeutics have?

    Audentes Therapeutics has 207 employees.

  • Who are Audentes Therapeutics competitors?

    Competitors of Audentes Therapeutics include MultiVir, Keros Therapeutics and GenePlanet.

  • Where is Audentes Therapeutics headquarters?

    Audentes Therapeutics headquarters is located at 600 California St 17th Floor, San Francisco, San Francisco.

  • Where are Audentes Therapeutics offices?

    Audentes Therapeutics has an office in San Francisco.

  • How many offices does Audentes Therapeutics have?

    Audentes Therapeutics has 1 office.